IMMUNOHISTOCHEMISTRY, CD 56

The IHC – CD56 (Cluster of Differentiation 56) test is an immunohistochemistry-based diagnostic assay used to detect CD56 protein expression in tissue samples. CD56, also known as Neural Cell Adhesion Molecule (NCAM), is a cell surface glycoprotein commonly expressed in natural killer (NK) cells, subsets of T lymphocytes, neural tissue, and neuroendocrine cells.

This test is widely used in pathology to diagnose and classify neuroendocrine tumors, small cell carcinomas, NK/T-cell lymphomas, and certain plasma cell disorders. CD56 expression helps pathologists determine tumor origin and supports accurate cancer classification.

Benefits of the Test

• Helps diagnose neuroendocrine tumors
• Assists in identifying NK/T-cell lymphomas
• Supports classification of small cell carcinomas
• Improves tumor differentiation and diagnostic accuracy
• Helps guide oncology treatment planning

Why Doctors Recommend This Test

Doctors recommend the IHC CD56 test when there is suspicion of neuroendocrine malignancies, lymphomas, or neural-origin tumors. It is commonly used in:

• Diagnosis of neuroendocrine tumors
• Small cell lung carcinoma evaluation
• NK/T-cell lymphoma classification
• Plasma cell neoplasm investigations
• Oncology biopsy interpretation

CD56 is frequently used alongside markers such as Synaptophysin, Chromogranin, NSE, CD3, CD20, and Ki-67 to achieve comprehensive tumor profiling and accurate diagnosis.

Preparation Before Test

No special preparation is required for this test. Important considerations include:

• The test is performed on a biopsy or surgical tissue sample
• No fasting or medication restrictions are necessary
• Clinical history and imaging findings may assist interpretation

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on specimen complexity and laboratory workflow.

Who Should Take This Test

• Patients with suspected neuroendocrine tumors
• Individuals with suspected NK/T-cell lymphoma
• Cases of small cell carcinoma evaluation
• Patients undergoing tumor biopsy classification
• Oncology patients requiring immunohistochemistry profiling

The IHC CD56 test is an important diagnostic tool in modern pathology and oncology. By detecting CD56 expression in tissue samples, it helps clinicians accurately identify neuroendocrine and lymphoid malignancies, supporting timely diagnosis and effective treatment planning.